Shopping Cart
Remove All
Your shopping cart is currently empty
Fezagepras (Setogepram) is an orally active GPR40 agonist and is an antagonist or inverse agonist of GPR84 with anti-inflammatory, anti-fibrotic, and anti-proliferative actions.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $48 | In Stock | In Stock | |
| 2 mg | $68 | In Stock | In Stock | |
| 5 mg | $97 | In Stock | In Stock | |
| 10 mg | $143 | In Stock | In Stock | |
| 25 mg | $258 | In Stock | In Stock | |
| 50 mg | $369 | In Stock | In Stock | |
| 100 mg | Preferential | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $94 | In Stock | In Stock |
| Description | Fezagepras (Setogepram) is an orally active GPR40 agonist and is an antagonist or inverse agonist of GPR84 with anti-inflammatory, anti-fibrotic, and anti-proliferative actions. |
| In vitro | TGF-β (10 ng/mL)-activated human hepatic stellate cells (HSCs) proliferation inhibited by Setogepram (PBI-4050; 500 μM; 24 hours). Setogepram (PBI-4050; 250 or 500 μM; 24hours) dose-dependently arrests HSCs at the G0/G1 phase without inducing apoptosis [2]. |
| In vivo | In type 2 diabetes eNOS-/-db/db mice, Setogepram (PBI-4050; 100 mg/kg/day; gavage from 8-20 weeks of age) markedly decreases hyperglycemia and markedly improve glucose tolerance [1]. |
| Synonyms | Setogepram, PBI-4050 |
| Molecular Weight | 206.28 |
| Formula | C13H18O2 |
| Cas No. | 1002101-19-0 |
| Smiles | CCCCCc1cccc(CC(O)=O)c1 |
| Relative Density. | no data available |
| Storage | Pure form: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 60 mg/mL (290.87 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+90% Saline: 5 mg/mL (24.24 mM), Sonication is recommeded. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.